The current state of radiotherapeutics is “the isotope wars” according to Jack Hoppin, CEO of Boston’s Ratio Therapeutics.
The current state of radiotherapeutics is “the isotope wars” according to Jack Hoppin, CEO of Boston’s Ratio Therapeutics.
As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a ...
Better treatment options have improved survival rates in the U.S., according to a report from the American Cancer Society.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback